Pharmacokinetics and Potency of Progestins used for Hormone Replacement Therapy and Contraception

@article{Stanczyk2004PharmacokineticsAP,
  title={Pharmacokinetics and Potency of Progestins used for Hormone Replacement Therapy and Contraception},
  author={Frank Z. Stanczyk},
  journal={Reviews in Endocrine and Metabolic Disorders},
  year={2004},
  volume={3},
  pages={211-224}
}
  • F. Stanczyk
  • Published 1 September 2002
  • Medicine
  • Reviews in Endocrine and Metabolic Disorders
View on Springer
ncbi.nlm.nih.gov
91 Citations
Highly Influential Citations
8
Background Citations
35
Methods Citations
4
Results Citations
1

91 Citations

Citation Type

Citation Type

Nomegestrol acetate-17b-estradiol for oral contraception
  • A. Burke
  • Medicine
  • Patient preference and adherence
  • 2013
TLDR
The bleeding pattern on NOMAC-E2 is characterized by fewer bleeding/spotting days, shorter withdrawal bleeds, and a higher incidence of amenorrhea than the comparator oral contraceptive containing drospirenone and ethinyl estradiol. Expand
Tailoring combination oral contraceptives to the individual woman.
TLDR
Assisted counseling to raise awareness of the specific characteristics of the different COC options available may optimize adherence and patient acceptability and offer improvements over their predecessors. Expand
Contraceptive progestins with androgenic properties stimulate breast epithelial cell proliferation
TLDR
Different progestins have distinct biological activities in the breast epithelium to be considered for more informed choices in hormonal contraception. Expand
Contraception for women with epilepsy: counseling, choices, and concerns
  • A. Reimers
  • Medicine
  • Open access journal of contraception
  • 2016
TLDR
Concerns are loss of bone mineral density and increased seizure activity due to hormonal effects and several studies show that a large proportion of WWE do not take their medicines regularly. Expand
Estrogens, progestins, and risk of breast cancer.
TLDR
There is a ceiling to the carcinogenic effect of estrogen on the breast; increases in nonsex hormone-binding globulin-bound estradiol (non-SHBG bound E2) exceeding approximately 10.2 pg/ml have no effect on breast cancer risk; this ceiling is lower than the lowest level seen during the menstrual cycle. Expand
New progestagens for contraceptive use.
TLDR
Several new progestins, including dienogest (DNG), drospirenone (DRSP), Nestorone (NES), nomegestrol acetate (NOMAc) and trimegestone (TMG) have been synthesized in the last two decades, designed to have no androgenic or estrogenic actions and to be closer to the physiological hormone P. Expand
An overview of menopausal oestrogen–progestin hormone therapy and breast cancer risk
Results from the Women's Health Initiative (WHI) trial support findings from observational studies that oestrogen–progestin therapy (EPT) use is associated with an increase in breast cancer risk. We… Expand
The woman patient after WHI.
TLDR
Women's different emotional reactions to and coping strategies for HT-related fear after WHI are discussed, as well as the meaning of the higher use of HT in postmenopausal highly-educated women and women gynaecologists. Expand
Effects of menopausal hormone therapy-based on the role of estrogens, progestogens, and their metabolites in proliferation of breast cancer cells.
  • Yu Deng, Hongyan Jin
  • Medicine
  • Cancer biology & medicine
  • 2021
TLDR
The biological effects of estrogen, progesterone, and their metabolites on the proliferation of breast cancer cells are described, based on relevant basic research and clinical trials, to improve understanding of the biological functions of estrogen and progestogen as well as the safety of MHT. Expand
Are the Effects of Oral and Vaginal Contraceptives on Bone Formation in Young Women Mediated via the Growth Hormone-IGF-I Axis?
TLDR
Changes in recombinant human GH-stimulated hepatic IGF-I synthesis in response to combined hormonal contraception (CHC) use are dependent on route of CHC administration, while the influence on PINP is route-independent. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 53 REFERENCES
Use of the name "Progestin".
TLDR
There is considerable confusion concerning the use of the term "progestin" in referring to progestational compounds and a consensus should be established to determine the generic name of progestations to avoid confusion and ambiguity in definition. Expand
A 1-year pharmacokinetic investigation of a novel oral contraceptive containing drospirenone in healthy female volunteers
TLDR
In conclusion, drospirenone was absorbed at a similar rate as other synthetic progestogens contained in various oral contraceptives, as indicated by similar tmax values. Expand
Drospirenone: pharmacology and pharmacokinetics of a unique progestogen.
TLDR
Based on the biochemical and pharmacodynamic data, drospirenone appears to be a viable alternative to the currently available progestogens. Expand
Improved Bioavailability of a Micronized Megestrol Acetate Tablet Formulation in Humans
TLDR
A significant increase in the drug bioavailability was observed, in either the rate or the extent of absorption, in a micronized megestrol acetate tablet formulation compared to a conventional form. Expand
Effect of low-dose oral contraceptives on androgenic markers and acne.
TLDR
Low-dose OC (EE, 20 micrograms) are effective in reducing circulating androgens and acne lesions without causing weight gain and, although LNG and NETA affected secondary markers differently, both OC formulations produced an equivalent decrease in bioavailable. Expand
Nomenclature of the gonane progestins.
TLDR
The use of gonane nomenclature to classify the levonorgestrel and norethindrone families of progestins, respectively, originates from the systemic name of these compounds. Expand
Determination of medrogestone in plasma by high-performance liquid chromatography.
TLDR
The developed method for plasma sample preparation and the evaluated HPLC condition were further applied to an in vivo pharmacokinetic study and prevented interference with the UV absorbance of medrogestone by endogenous steroids in plasma by reacting plasma with oxalyl chloride. Expand
In vivo conversion of norethisterone and norethisterone acetate to ethinyl etradiol in postmenopausal women.
TLDR
It is concluded that at therapeutic doses of the progestogens, the exposure to metabolically derived ethinyl estradiol is probably of little clinical significance not only in fertile women using oral contraceptive combination preparations containing norethisterone and ethinyl Estradiol, but also in postmenopausal women who receive oral doses of estradio for estrogen replacement. Expand
INTRODUCTION : STRUCTURE-FUNCTION RELATIONSHIPS, METABOLISM PHARMACOKINETICS AND POTENCY OF PROGESTINS
Plasma concentrations of medroxyprogesterone acetate, estradiol and estrone following oral administration of Klimaxil, Trisequence/Provera and Divina. A randomized, single-blind, triple cross-over bioavailability study in menopausal women.
TLDR
There was no statistically significant difference between the drugs with respect to the estradiol levels, and Divina produced higher MPA concentrations than Klimaxil and the combination of Trisequence and Provera, although the mean AUC was not twice as high, as might have been expected. Expand
...
1
2
3
4
5
...